RNASEL and MIR146A SNP-SNP interaction as a susceptibility factor for non-melanoma skin cancer

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Farzan, Shohreh F ^a   Karagas, Margaret R ^a   Christensen, Brock C ^a   Li, Zhongze ^a   Kuriger, Jacquelyn K ^b   Nelson, Heather H ^b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 146A; RIBONUCLEASE L; 2-5A-DEPENDENT RIBONUCLEASE; MICRORNA; MIRN146 MICRORNA, HUMAN; RIBONUCLEASE;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENE LOCUS; GENE TARGETING; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIR146A GENE; NON MELANOMA SKIN CANCER; POPULATION RESEARCH; RNA METABOLISM; RNASEL GENE; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN CARCINOMA; TUMOR GENE; WILD TYPE; GENETIC PREDISPOSITION; GENETICS; MELANOMA; SKIN TUMOR; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; ENDORIBONUCLEASES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MELANOMA; MICRORNAS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SKIN NEOPLASMS;

EID: 84899436770     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093602     Document Type: Article

References (70)

1. NCI Skin Cancer.
2. Kim RH, Armstrong AW (2012) Nonmelanoma skin cancer. Dermatol Clin 30: 125-139, ix.
3. Chen AC, Halliday GM, Damian DL (2013) Non-melanoma skin cancer: carcinogenesis and chemoprevention. Pathology 45: 331-341.
4. Madan V, Lear JT, Szeimies RM (2010) Non-melanoma skin cancer. Lancet 375: 673-685.
5. Karagas MR, Weinstock MA, Nelson HH (2006) Keratinocyte Carcinomas (Basal and Squamous Cell Carcinomas of the Skin). In: Schottenfeld D, Fraumeni JF, editors. Cancer Epidemiology and Prevention. Third Ed. ed. New York, NY: Oxford University Press.
6. Euvrard S, Kanitakis J, Claudy A (2003) Skin cancers after organ transplantation. N Engl J Med 348: 1681-1691. (Pubitemid 36459475)
7. Karagas MR, Cushing GL, Jr., Greenberg ER, Mott LA, Spencer SK, et al. (2001) Non-melanoma skin cancers and glucocorticoid therapy. Br J Cancer 85: 683-686. (Pubitemid 32929465)
8. Lindelof B, Sigurgeirsson B, Gabel H, Stern RS (2000) Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol 143: 513-519.
9. Moloney FJ, Comber H, Conlon PJ, Murphy GM (2006) The role of immunosuppression in the pathogenesis of basal cell carcinoma. Br J Dermatol 154: 790-791. (Pubitemid 43374120)
10. Urosevic M, Dummer R (2004) Role of imiquimod in skin cancer treatment. Am J Clin Dermatol 5: 453-458. (Pubitemid 40175263)
11. So AY, Zhao JL, Baltimore D (2013) The Yin and Yang of microRNAs: leukemia and immunity. Immunol Rev 253: 129-145.
12. Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR, et al. (2008) Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci U S A 105: 7269-7274. (Pubitemid 351754467)
13. Jazdzewski K, Liyanarachchi S, Swierniak M, Pachucki J, Ringel MD, et al. (2009) Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer. Proc Natl Acad Sci U S A 106: 1502-1505.
14. Gazouli M, Papaconstantinou I, Stamatis K, Vaiopoulou A, Zeglinas C, et al. (2013) Association Study of Genetic Variants in miRNAs in Patients with Inflammatory Bowel Disease: Preliminary Results. Dig Dis Sci.
15. Wu D, Wang F, Dai WQ, He L, Lu J, et al. (2013) The miR-146a rs2910164 G>C polymorphism and susceptibility to digestive cancer in Chinese. Asian Pac J Cancer Prev 14: 399-403.
16. Wei WJ, Wang YL, Li DS, Wang Y, Wang XF, et al. (2013) Association between the rs2910164 polymorphism in pre-Mir-146a sequence and thyroid carcinogenesis. PLoS One 8: e56638.
17. TargetScanHuman: Prediction of microRNA targets. Whitehead Institute for Biomedical Research.
18. Bisbal C, Silverman RH (2007) Diverse functions of RNase L and implications in pathology. Biochimie 89: 789-798. (Pubitemid 47008946)
19. Li XL, Andersen JB, Ezelle HJ, Wilson GM, Hassel BA (2007) Post-transcriptional regulation of RNase-L expression is mediated by the 3′-untranslated region of its mRNA. J Biol Chem 282: 7950-7960. (Pubitemid 47093551)
20. Lee TY, Ezelle HJ, Venkataraman T, Lapidus RG, Scheibner KA, et al. (2013) Regulation of human RNase-L by the miR-29 family reveals a novel oncogenic role in chronic myelogenous leukemia. J Interferon Cytokine Res 33: 34-42.
21. Xiang Y, Wang Z, Murakami J, Plummer S, Klein EA, et al. (2003) Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2′,5′-oligoadenylates. Cancer Res 63: 6795-6801. (Pubitemid 37322961)
22. Andersen JB, Li XL, Judge CS, Zhou A, Jha BK, et al. (2007) Role of 2-5A-dependent RNase-L in senescence and longevity. Oncogene 26: 3081-3088. (Pubitemid 46733645)
23. Castelli JC, Hassel BA, Wood KA, Li XL, Amemiya K, et al. (1997) A study of the interferon antiviral mechanism: apoptosis activation by the 2-5A system. J Exp Med 186: 967-972. (Pubitemid 27407357)
24. Hassel BA, Zhou A, Sotomayor C, Maran A, Silverman RH (1993) A dominant negative mutant of 2-5A-dependent RNase suppresses antiproliferative and antiviral effects of interferon. EMBO J 12: 3297-3304. (Pubitemid 23232761)
25. Casey G, Neville PJ, Plummer SJ, Xiang Y, Krumroy LM, et al. (2002) RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet 32: 581-583. (Pubitemid 35435169)
26. Cybulski C, Wokolorczyk D, Jakubowska A, Gliniewicz B, Sikorski A, et al. (2007) DNA variation in MSR1, RNASEL and E-cadherin genes and prostate cancer in Poland. Urol Int 79: 44-49. (Pubitemid 47051818)
27. Daugherty SE, Hayes RB, Yeager M, Andriole GL, Chatterjee N, et al. (2007) RNASEL Arg462Gln polymorphism and prostate cancer in PLCO. Prostate 67: 849-854. (Pubitemid 46828938)
28. Fesinmeyer MD, Kwon EM, Fu R, Ostrander EA, Stanford JL (2011) Genetic variation in RNASEL and risk for prostate cancer in a population-based case-control study. Prostate.
29. Kruger S, Engel C, Bier A, Silber AS, Gorgens H, et al. (2007) The additive effect of p53 Arg72Pro and RNASEL Arg462Gln genotypes on age of disease onset in Lynch syndrome patients with pathogenic germline mutations in MSH2 or MLH1. Cancer Lett 252: 55-64. (Pubitemid 46734555)
30. Kruger S, Silber AS, Engel C, Gorgens H, Mangold E, et al. (2005) Arg462Gln sequence variation in the prostate-cancer-susceptibility gene RNASEL and age of onset of hereditary non-polyposis colorectal cancer: a case-control study. Lancet Oncol 6: 566-572. (Pubitemid 41051934)
31. Bartsch DK, Fendrich V, Slater EP, Sina-Frey M, Rieder H, et al. (2005) RNASEL germline variants are associated with pancreatic cancer. Int J Cancer 117: 718-722. (Pubitemid 41598821)
32. Zhang LF, Mi YY, Qin C, Wang Y, Cao Q, et al. (2011) RNASEL -1385G/A polymorphism and cancer risk: a meta-analysis based on 21 case-control studies. Mol Biol Rep 38: 5099-5105.
33. Karagas MR, McDonald JA, Greenberg ER, Stukel TA, Weiss JE, et al. (1996) Risk of basal cell and squamous cell skin cancers after ionizing radiation therapy. For The Skin Cancer Prevention Study Group. J Natl Cancer Inst 88: 1848-1853. (Pubitemid 26425060)
34. Karagas MR, Greenberg ER, Spencer SK, Stukel TA, Mott LA (1999) Increase in incidence rates of basal cell and squamous cell skin cancer in New Hampshire, USA. New Hampshire Skin Cancer Study Group. Int J Cancer 81: 555-559. (Pubitemid 29203052)
35. Karagas MR, Nelson HH, Sehr P, Waterboer T, Stukel TA, et al. (2006) Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin. J Natl Cancer Inst 98: 389-395.
36. Karagas MR, Waterboer T, Li Z, Nelson HH, Michael KM, et al. (2010) Genus beta human papillomaviruses and incidence of basal cell and squamous cell carcinomas of skin: population based case-control study. BMJ 341: c2986.
37. Kricker A, Armstrong BK, English DR (1994) Sun exposure and non-melanocytic skin cancer. Cancer Causes Control 5: 367-392. (Pubitemid 24205565)
38. Kricker A, Armstrong BK, English DR, Heenan PJ (1991) Pigmentary and cutaneous risk factors for non-melanocytic skin cancer - a case-control study. Int J Cancer 48: 650-662.
39. Miettinen O (1976) Estimability and estimation in case-referent studies. Am J Epidemiology 103: 226-235.
40. Breslow NE, Day NE (1980) Statistical Methods in Cancer Research Volume 1 - The Analysis of Case-Control Studies. Lyon, France: IARC.
41. Leonardi-Bee J, Ellison T, Bath-Hextall F (2012) Smoking and the risk of nonmelanoma skin cancer: systematic review and meta-analysis. Arch Dermatol 148: 939-946.
42. Welsh MM, Karagas MR, Applebaum KM, Spencer SK, Perry AE, et al. (2008) A role for ultraviolet radiation immunosuppression in non-melanoma skin cancer as evidenced by gene-environment interactions. Carcinogenesis 29: 1950-1954.
43. Welsh MM, Karagas MR, Kuriger JK, Houseman A, Spencer SK, et al. (2011) Genetic determinants of UV-susceptibility in non-melanoma skin cancer. PLoS One 6: e20019.
44. Rennert H, Zeigler-Johnson CM, Addya K, Finley MJ, Walker AH, et al. (2005) Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men. Cancer Epidemiol Biomarkers Prev 14: 949-957. (Pubitemid 40478562)
45. Ezelle HJ, Hassel BA (2012) Pathologic effects of RNase-L dysregulation in immunity and proliferative control. Front Biosci (Schol Ed) 4: 767-786.
46. Madsen BE, Ramos EM, Boulard M, Duda K, Overgaard J, et al. (2008) Germline mutation in RNASEL predicts increased risk of head and neck, uterine cervix and breast cancer. PLoS One 3: e2492.
47. Urisman A, Molinaro RJ, Fischer N, Plummer SJ, Casey G, et al. (2006) Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog 2: e25.
48. Farzan SF, Waterboer T, Gui J, Nelson HH, Li Z, et al. (2013) Cutaneous alpha, beta and gamma human papillomaviruses in relation to squamous cell carcinoma of the skin: A population-based study. International Journal of Cancer: n/a-n/a.
49. Bouwes Bavinck JN, Neale RE, Abeni D, Euvrard S, Green AC, et al. (2010) Multicenter study of the association between betapapillomavirus infection and cutaneous squamous cell carcinoma. Cancer Res 70: 9777-9786.
50. Andersson K, Michael KM, Luostarinen T, Waterboer T, Gislefoss R, et al. (2012) Prospective study of human papillomavirus seropositivity and risk of nonmelanoma skin cancer. Am J Epidemiol 175: 685-695.
51. Iannacone MR, Gheit T, Waterboer T, Giuliano AR, Messina JL, et al. (2012) Case-control study of cutaneous human papillomaviruses in squamous cell carcinoma of the skin. Cancer Epidemiol Biomarkers Prev 21: 1303-1313.
52. Quinn SR, O'Neill LA (2011) A trio of microRNAs that control Toll-like receptor signalling. Int Immunol 23: 421-425.
53. Boldin MP, Taganov KD, Rao DS, Yang L, Zhao JL, et al. (2011) miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med 208: 1189-1201.
54. Etzrodt M, Cortez-Retamozo V, Newton A, Zhao J, Ng A, et al. (2012) Regulation of monocyte functional heterogeneity by miR-146a and Relb. Cell Rep 1: 317-324.
55. Taganov KD, Boldin MP, Chang KJ, Baltimore D (2006) NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A 103: 12481-12486. (Pubitemid 44267285)
56. Chatzikyriakidou A, Voulgari PV, Georgiou I, Drosos AA (2010) A polymorphism in the 39-UTR of interleukin-1 receptor-associated kinase (IRAK1), a target gene of miR-146a, is associated with rheumatoid arthritis susceptibility. Joint Bone Spine 77: 411-413.
57. Chatzikyriakidou A, Voulgari PV, Georgiou I, Drosos AA (2010) The role of microRNA-146a (miR-146a) and its target IL-1R-associated kinase (IRAK1) in psoriatic arthritis susceptibility. Scand J Immunol 71: 382-385.
58. Cheng HS, Sivachandran N, Lau A, Boudreau E, Zhao JL, et al. (2013) MicroRNA-146 represses endothelial activation by inhibiting pro-inflammatory pathways. EMBO Molecular Medicine: n/a-n/a.
59. Tang Y, Luo X, Cui H, Ni X, Yuan M, et al. (2009) MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum 60: 1065-1075.
60. Orsos Z, Szanyi I, Csejtei A, Gerlinger I, Ember I, et al. (2013) Association of pre-miR-146a rs2910164 polymorphism with the risk of head and neck cancer. Anticancer Res 33: 341-346.
61. Lian H, Wang L, Zhang J (2012) Increased risk of breast cancer associated with CC genotype of Has-miR-146a Rs2910164 polymorphism in Europeans. PLoS One 7: e31615.
62. Xu B, Feng NH, Li PC, Tao J, Wu D, et al. (2010) A functional polymorphism in Pre-miR-146a gene is associated with prostate cancer risk and mature miR-146a expression in vivo. Prostate 70: 467-472.
63. Yue C, Wang M, Ding B, Wang W, Fu S, et al. (2011) Polymorphism of the pre-miR-146a is associated with risk of cervical cancer in a Chinese population. Gynecol Oncol 122: 33-37.
64. Zhou F, Zhu H, Luo D, Wang M, Dong X, et al. (2012) A functional polymorphism in Pre-miR-146a is associated with susceptibility to gastric cancer in a Chinese population. DNA Cell Biol 31: 1290-1295.
65. Ma L, Zhu L, Gu D, Chu H, Tong N, et al. (2013) A genetic variant in miR-146a modifies colorectal cancer susceptibility in a Chinese population. Arch Toxicol 87: 825-833.
66. Yin Z, Yan L, Cui Z, Li X, Ren Y, et al. (2013) Effects of common polymorphisms rs2910164 in miR-146a and rs3746444 in miR-499 on cancer susceptibility: a meta-analysis. Mol Biol Rep 40: 3003-3013.
67. Wang AX, Xu B, Tong N, Chen SQ, Yang Y, et al. (2012) Meta-analysis confirms that a common G/C variant in the pre-miR-146a gene contributes to cancer susceptibility and that ethnicity, gender and smoking status are risk factors. Genet Mol Res 11: 3051-3062.
68. Thornton MJ (2002) The biological actions of estrogens on skin. Exp Dermatol 11: 487-502.
69. Nguyen LH, Espert L, Mechti N, Wilson DM, 3rd (2001) The human interferon- and estrogen-regulated ISG20/HEM45 gene product degrades single-stranded RNA and DNA in vitro. Biochemistry 40: 7174-7179. (Pubitemid 32554041)
70. Pentecost BT (1998) Expression and estrogen regulation of the HEM45 MRNA in human tumor lines and in the rat uterus. J Steroid Biochem Mol Biol 64: 25-33.